Skip to main content
. 2021 Jul 15;138:104224. doi: 10.1016/j.mvr.2021.104224

Fig. 3.

Fig. 3

Several biomarkers for endothelial dysfunction and the outcome of COVID-19. Patients presenting with a higher plasma levels of (A) von Willebrand Factor (VWF) antigen; (B) tissue-type plasminogen activator (t-PA); (C) plasminogen activator inhibitor-1 antigen (PAI-1) antigen; and (D) soluble thrombomodulin (sTM) have an increased risk of composite poor outcome.